56 citations,
November 2007 in “Molecular and cellular endocrinology” Two enzymes regulate androgen receptor activity, affecting treatments for androgen insufficiency and benign prostatic hyperplasia.
October 2005 in “Archives of Dermatological Research” Large prostate patients more likely to have hair loss.
2 citations,
November 2017 in “Biotechnology Letters” Researchers found four natural compounds that can change DHT levels in prostate cancer cells.
August 2008 in “Current Opinion in Internal Medicine” In 2007, prostate cancer research improved understanding of risk, diagnosis, and treatment, but also showed heart risks with certain therapies and the need for personalized care.
23 citations,
July 1993 in “Pharmacotherapy” Finasteride treats enlarged prostate and baldness, but may cause limited urinary improvement and sex-related side effects.
September 2019 in “Human Andrology” Higher serum androgens contribute to male pattern baldness.
June 2007 in “Endocrinology and Metabolism Clinics of North America” The document covers various male health issues, their causes, treatments, and related conditions.
3 citations,
May 2003 in “BJUI” Doxazosin alone or combined with finasteride improves prostate symptoms better than finasteride alone, without extra benefits.
17 citations,
January 2016 in “American Journal of Epidemiology” Men with male pattern baldness have a higher risk of dying from prostate cancer.
November 2011 in “InTech eBooks” Prostate cancer risk is not linked to blood testosterone levels.
10 citations,
December 2014 in “PubMed” Finasteride, a hair loss drug, may cause sexual dysfunction and depression, but these effects are usually temporary and the drug is generally safe. More research is needed.
15 citations,
December 2006 in “Clinical interventions in aging” 5 alpha-reductase inhibitors like finasteride may lower prostate cancer risk and improve cancer screening.
April 2012 in “The Journal of Urology” Early baldness increases prostate cancer risk, radiotherapy and surgery have similar second cancer rates, and ALA may reduce prostate cancer risk.
9 citations,
September 2010 in “Dermatologic Therapy” Finasteride for hair loss is safe and does not increase the risk of high-grade prostate cancer.
October 2017 in “Universidad Nacional de Trujillo” Low doses of Coffea arabica seed extract prevent prostate growth and lower uric acid and PSA levels.
11 citations,
April 2013 in “Journal of Agricultural and Food Chemistry” Monascus helps prevent baldness, prostate issues, and may be a natural alternative to medications.
1 citations,
January 2020 in “Egyptian Journal of Dermatology and Venereology” Higher testosterone and DHT levels are linked to hair loss in men, but not to prostate cancer risk.
Androgen-modulating drugs do not significantly change the heat sensitivity of prostate cancer cells.
86 citations,
March 1993 in “Toxicology and Applied Pharmacology” Finasteride affects male rat genitalia development, causing abnormalities during specific pregnancy days.
August 2017 in “Revista de la Facultad de Ciencias Médicas (Quito)/Revista de la Facultad de Ciencias Médicas” Early baldness in men may indicate a higher risk of prostate cancer.
14 citations,
March 2001 in “Psychiatric Services” Older men should openly discuss sexual health with doctors to improve their quality of life.
32 citations,
May 2006 in “The Journal of Urology” Using finasteride with TIP extends time off period for prostate cancer patients.
88 citations,
February 2008 in “Journal of Medicinal Chemistry” Scientists made the first metal-based compounds from a nonsteroidal antiandrogen drug, which showed potential in fighting both hormone-dependent and independent prostate cancer cells.
38 citations,
July 2012 in “international journal of endocrinology and metabolism” Some plant-derived compounds may help with hormonal conditions, but more research is needed to confirm their effectiveness.
January 2008 in “The Year book of endocrinology” Gene variant linked to prostate cancer, hormone levels, and hair loss.
4 citations,
December 2013 in “Archivio italiano di urologia, andrologia” Dutasteride reduces hospitalization and prostate cancer risk compared to finasteride, potentially offsetting its higher cost.
6 citations,
September 1997 in “Prostate Cancer and Prostatic Diseases” Finasteride 5 mg effectively reduces urinary symptoms and PSA levels in men with enlarged prostates, with few sexual side effects.
February 2012 in “Community oncology” The document concludes that accurately identifying leukemia types is crucial, and the risks of cancer from finasteride need careful evaluation against its benefits.
March 2012 in “Dermatology Times E-News” Men with pattern baldness may have a higher risk of prostate issues.
21 citations,
April 1998 in “Urology” Finasteride effectively treats BPH and hair loss but may cause sexual side effects.